CL2020001156A1 - Formulaciones de liberación prolongada para aplicaciones intra-articulares. - Google Patents

Formulaciones de liberación prolongada para aplicaciones intra-articulares.

Info

Publication number
CL2020001156A1
CL2020001156A1 CL2020001156A CL2020001156A CL2020001156A1 CL 2020001156 A1 CL2020001156 A1 CL 2020001156A1 CL 2020001156 A CL2020001156 A CL 2020001156A CL 2020001156 A CL2020001156 A CL 2020001156A CL 2020001156 A1 CL2020001156 A1 CL 2020001156A1
Authority
CL
Chile
Prior art keywords
intra
extended release
release formulations
carboxamide
pyridin
Prior art date
Application number
CL2020001156A
Other languages
English (en)
Spanish (es)
Inventor
Carlo Castagnoli
Andreas Fisch
Mathilde Lorscheider
Manjali Laxman Neharkar
Bernd Ulrich Riebesehl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020001156A1 publication Critical patent/CL2020001156A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2020001156A 2017-11-10 2020-05-04 Formulaciones de liberación prolongada para aplicaciones intra-articulares. CL2020001156A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US201862743864P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
CL2020001156A1 true CL2020001156A1 (es) 2020-10-30

Family

ID=64402238

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001156A CL2020001156A1 (es) 2017-11-10 2020-05-04 Formulaciones de liberación prolongada para aplicaciones intra-articulares.

Country Status (23)

Country Link
US (1) US20210177824A1 (enExample)
EP (1) EP3706710B1 (enExample)
JP (1) JP7284750B2 (enExample)
KR (1) KR20200087138A (enExample)
CN (1) CN111278410A (enExample)
AU (1) AU2018364685B2 (enExample)
CA (1) CA3075722A1 (enExample)
CL (1) CL2020001156A1 (enExample)
DK (1) DK3706710T3 (enExample)
ES (1) ES2981903T3 (enExample)
FI (1) FI3706710T3 (enExample)
HR (1) HRP20240808T1 (enExample)
HU (1) HUE066971T2 (enExample)
IL (2) IL305541A (enExample)
LT (1) LT3706710T (enExample)
MX (2) MX2020004477A (enExample)
PL (1) PL3706710T3 (enExample)
PT (1) PT3706710T (enExample)
RS (1) RS65659B1 (enExample)
SA (1) SA520411881B1 (enExample)
SI (1) SI3706710T1 (enExample)
TW (2) TW202400164A (enExample)
WO (1) WO2019092637A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015735B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
KR20220076371A (ko) * 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
RS66122B1 (sr) 2014-05-13 2024-11-29 Novartis Ag Jedinjenja i kompozicije za indukciju hondrogeneze

Also Published As

Publication number Publication date
KR20200087138A (ko) 2020-07-20
HUE066971T2 (hu) 2024-09-28
BR112020008806A2 (pt) 2020-10-20
PL3706710T3 (pl) 2024-08-05
CA3075722A1 (en) 2019-05-16
TW202400164A (zh) 2024-01-01
RU2020115439A (ru) 2021-12-10
AU2018364685A1 (en) 2020-03-26
IL274149B1 (en) 2023-10-01
MX2023007036A (es) 2023-06-28
TW201922245A (zh) 2019-06-16
JP2021502337A (ja) 2021-01-28
DK3706710T3 (da) 2024-07-08
AU2018364685B2 (en) 2021-05-20
RU2020115439A3 (enExample) 2021-12-10
SA520411881B1 (ar) 2024-01-04
HRP20240808T1 (hr) 2024-09-27
MX2020004477A (es) 2020-08-03
CN111278410A (zh) 2020-06-12
RS65659B1 (sr) 2024-07-31
PT3706710T (pt) 2024-06-27
US20210177824A1 (en) 2021-06-17
EP3706710B1 (en) 2024-04-10
SI3706710T1 (sl) 2024-08-30
JP7284750B2 (ja) 2023-05-31
TWI813597B (zh) 2023-09-01
LT3706710T (lt) 2024-07-10
EP3706710A1 (en) 2020-09-16
IL274149B2 (en) 2024-02-01
ES2981903T3 (es) 2024-10-14
WO2019092637A1 (en) 2019-05-16
IL274149A (en) 2020-06-30
IL305541A (en) 2023-10-01
FI3706710T3 (fi) 2024-07-08

Similar Documents

Publication Publication Date Title
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
PH12022550611A1 (en) Brd9 bifunctional degraders and their methods of use
ZA202301086B (en) Injectable formulation
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
PE20180601A1 (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
AR106776A1 (es) Composiciones de cuidado oral
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
EA202090965A1 (ru) Водные композиции биластина
AR113822A1 (es) Formulaciones de liberación extendida para aplicaciones intra-articulares
EA202090172A1 (ru) Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью